Pilot Study to Assess the Safety and Efficacy of Switching the Nnrti or pi to Maraviroc in Hiv-1-infected Subjects With Persistent Viremia Suppression.

Trial Profile

Pilot Study to Assess the Safety and Efficacy of Switching the Nnrti or pi to Maraviroc in Hiv-1-infected Subjects With Persistent Viremia Suppression.

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Jan 2013

At a glance

  • Drugs Maraviroc (Primary) ; Antiretrovirals; Atazanavir; Atazanavir/ritonavir; Darunavir; Darunavir/ritonavir; Efavirenz; Fosamprenavir; Lopinavir/ritonavir; Nevirapine; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors; Ritonavir; Tipranavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms MARAVI-SWITCH
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Jan 2013 Primary endpoint 'Viral-load' has been met.
    • 01 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top